DTRA Awards Mount Sinai $20.7M for Inhaled mRNA Vaccine Research
The Defense Threat Reduction Agency awarded Icahn School of Medicine at Mount Sinai an approximately $20.7 million, five-year agreement through its RAVEN program. The effort will develop and evaluate an inhaled/nasal mRNA vaccine platform, initially targeting H5N1 and assessing adaptability to at least 20 respiratory viruses; it is an award, not an open solicitation.
Key Signals
- DTRA commits approximately $20.7M to inhaled/nasal mRNA vaccine research
- Five-year RAVEN agreement runs through August 28, 2031
- Initial research target is H5N1, with adaptability assessed across at least 20 respiratory viruses
- Treat the award as a market signal; no open solicitation or specific subcontract opportunity is identified
The Defense Threat Reduction Agency (DTRA), through its RAVEN program, awarded the Icahn School of Medicine at Mount Sinai an approximately $20.7 million agreement to develop and evaluate an inhaled/nasal messenger RNA (mRNA) vaccine platform. The five-year research effort is scheduled to run through August 28, 2031. Its initial target is H5N1, while the work will also assess whether the platform can be adapted to at least 20 respiratory viruses. The award is a funded research effort, not an open solicitation or an invitation for vendors to submit proposals.
Agencies
- U.S. Department of Defense
- Defense Threat Reduction Agency
- Joint Science and Technology Office
- Medical CBRN Defense Consortium
Vendors
- Icahn School of Medicine at Mount Sinai
Locations
- Mount Sinai